Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Ausztrália3. fázis

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

A legfontosabb adatok

Ki végzi
Martin Schrappe
Hol
Sydney és Westmead (Ausztrália)Mind a 2 helyszín megnézéseMég 7 másik országban, 114 helyszínen
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
5000 fő, tervezett
Kezdés
2018. júl. 15.
Várható befejezés
2028. júl. 14.
A vizsgálat típusa
Beavatkozással járó, 12 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Blinatumomab
  • Bortezomib
  • Cyclophosphamide
  • Cytarabine
  • Daunorubicin
  • Myocet
  • Dexamethasone
  • Doxorubicin
  • Etoposide
  • Fludarabine Phosphate
  • Ifosfamide
  • 6-Mercaptopurine
  • Methotrexate
  • Pegaspargase
  • Prednisolone
  • Tioguanin
  • Vincristine
  • Vindesine
  • Erwinase
A regiszteradat frissítve
2025. április 6.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat 18 évnél fiatalabb, újonnan diagnosztizált akut limfoblasztos leukémiás (ALL) vagy ahhoz közel álló akut leukémiás gyermekeket és kamaszokat keres, akiket részt vevő központban kezelnek.

Életkor
18 évnél fiatalabb (legfeljebb 17 év és 365 nap) a diagnózis napján.
Nem
Minden nemű beteg csatlakozhat.
A betegség stádiuma
Újonnan diagnosztizált akut limfoblasztos leukémia, ALL-kezeléssel kezelt kevert fenotípusú akut leukémia (MPAL), vagy akut differenciálatlan leukémia.
Korábbi kezelés
Nem kaphatott korábban citosztatikus gyógyszert. A diagnózis előtti hónapban nem kaphatott 1 mg/kg/nap vagy annál több glükokortikoidot két hétnél tovább. A kezelés kezdete előtti 2 hétben nem kaphatott élő oltást.
Biomarker vagy leletérték
Ph+ (BCR-ABL1 vagy t(9;22)-pozitív) ALL esetén nem lehet csatlakozni.

A részvétel fő kizáró okai

  • Ph+ (BCR-ABL1 vagy t(9;22)-pozitív) ALL
  • Korábbi kemoterápia vagy sugárkezelés után második daganatként felfedezett leukémia
  • Más betegség, amely miatt a protokoll szerinti kezelés nem lehetséges
  • Terhesség vagy szoptatás
  • Részvétel másik klinikai vizsgálatban (a jóváhagyott támogató kezelési kiegészítő vizsgálatok kivételével)

A regiszter feltételei, szó szerint

Mind a 19 feltétel megnézéseKevesebb

Ki vehet részt

  • newly diagnosed acute lymphoblastic leukemia or
  • newly diagnosed mixed phenotype acute leukemia (MPAL) meeting one of the following criteria:
  • biphenotypic with a dominant T or B lineage assignment
  • bilineal either with a dominant lymphoblastic population or if another reasonable rationale exists to treat the patient with an ALL-based therapy regimen
  • newly diagnosed acute undifferentiated leukemia
  • age < 18 years (up to 17 years and 365 days) at the day of diagnosis
  • patient enrolled in a participating center
  • written informed consent to trial participation and transfer and processing of data A subsequent removal from the study is only allowed if the inclusion criteria turn out not to be fulfilled or in the case of pregnancy of the patient

Ki nem vehet részt

  • pre-treatment with cytostatic drugs
  • glucocorticoid pre-treatment with ≥ 1 mg/kg/d for more than two weeks during the last month before diagnosis
  • Sexually active adolescents not willing to use highly effective contraceptive method (pearl index <1) until 12 months after end of anti-leukemic therapy
  • live vaccine immunization within 2 weeks before start of protocol treatment
  • underlying disease that does not allow treatment according to the protocol (e.g. severe congenital heart disease, Charcot-Marie Syndrome, Ataxia-teleangiectasia…)
  • ALL diagnosed as second malignancy and preceding chemotherapy and/or radiotherapy
  • Ph+ (BCR-ABL1 or t(9;22)-positive) ALL
  • bilineal leukemia with a lymphoblastic and a separate non-lymphoblastic (≥ 10% of total cells) blast subset
  • treatment started according to another protocol
  • evidence of pregnancy or lactation period
  • participation in another clinical trial except for add-on trials within the scope of supportive care approved by the sponsor

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • How old is the patient who may join a trial?
  • What type of cancer has the patient been diagnosed with?
  • Is this cancer newly diagnosed, or has it come back or not responded to treatment?
  • Is the patient pregnant or breastfeeding?

Helyszínek itt: Ausztrália

Még 7 másik országban, 114 helyszínen

  • Sydney Children's HospitalSydney, AusztráliaContact: Draga BarbaricRésztvevőt keres
  • The Children's Hospital at WestmeadWestmead, AusztráliaContact: Luciano Dalla-PozzaRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The understanding of acute lymphoblastic leukemia (ALL) in childhood and adolescence has largely changed due to extensive genetic research in recent years: ALL is now considered to be a very heterogeneous disease group. The leukemia cells present themselves with quite differently activated regulatory mechanisms of the malignant phenotype. The introduction of more accurate methods of assessing therapy response ("minimal residual disease [MRD] tests") has provided new insights into very different mechanisms of action, including factors influenced by host factors; this has had practical clinical consequences for the use of more individualized therapy. Multimodal therapies have enabled a cure level of over 80% for ALL in this age group. However, the own and international study data show that the therapy toxicity of the contemporary chemotherapy concepts has become unacceptably high, in particular with respect to those intensified therapies used for the treatment of patients at high risk of ALL relapse.

A teljes eredeti leírásKevesebb

The AIEOP-BFM ALL 2017 study therefore aims for an innovative integrated approach that will not only adapt the risk stratification to new prognostic markers using more comprehensive diagnostics, but above all, qualitatively reorient the therapy. The most important consequence will be that this study is testing immunotherapy with the bispecific antibody blinatumomab as an alternative to particularly intensive and toxic chemotherapy elements in precursor B-cell ALL (pB-ALL) patients with detectable chemotherapy resistance and at high risk of relapse. With the aim to complement the effects of the conventional chemotherapy, Blinatumomab is in addition tested in the large group of pB-ALL patients at intermediate relapse risk with seemingly unremarkable leukemia, but who account for a large proportion of all relapses. Targeted therapy is also used in the form of the proteasome inhibitor bortezomib for patients with pB-ALL and slow response to the drugs of the induction chemotherapy with the aim to overcome intrinsic chemotherapy resistance of the ALL cells. In patients with T-lineage ALL, who have particularly poor chances for cure after relapse, the established consolidation chemotherapy has proved to be particularly effective. This chemotherapy phase is therefore tested in a longer and more intensive form in such T-ALL patients with intermediate or slow early treatment response with the aim to reduce the relapses rate in this subgroup.

A vizsgálat 12 csoportja

  • pB: early (non-)HR-standard/MR-standardMár használt kezelés, összehasonlításként

    Induction (5 wks): "Protocol IA" with prednisolone, vincristine, daunorubicin, pegaspargase, IT methotrexate (MTX) Consolidation (6 w/4 w): "Consolidation extended" (control arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-mercaptopurine (6-MP), IT MTX, dexamethasone, vincristine, pegaspargase or "Consolidation short" (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX Extra-compartment phase (8 wks): "Protocol M" with 6-MP, HD-MTX, IT MTX Reinduction (6 wks): "Protocol II" with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine Maintenance (until 2 years after initial diagnosis): 6-MP, MTX \[without preceding blinatumomab (control arm of randomization R-MR)\] Erwinase is given in case of allergy to pegaspargase.

    Kezelés: Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Tioguanin, Vincristine és Erwinase

  • pB: early HR-exp./MR-standardA vizsgált kezelés

    Induction (5 w): "Protocol IA" with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX Consolidation (6 w): "Consolidation extended+BZM" (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59) Extra-compartment phase (8 wks): "Protocol M" with 6-MP, HD-MTX, IT MTX Reinduction (6 wks): "Protocol II" with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX \[without preceding blinatumomab (control arm of randomization R-MR)\] Erwinase is given in case of allergy to pegaspargase.

    Kezelés: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Tioguanin, Vincristine és Erwinase

  • pB: early (non)HR-standard/MR-exp.A vizsgált kezelés

    Induction (5 w): "Protocol IA" with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX Consolidation (6 w/4 w): "Consolidation extended" (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or "Consolidation short" (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX Extra-compartment phase (8 w): "Protocol M" with 6-MP, HD-MTX, IT MTX Reinduction (6 w): "Protocol II" with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR) Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX Erwinase is given in case of allergy to pegaspargase.

    Kezelés: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Tioguanin, Vincristine és Erwinase

  • pB: early HR-exp./MR-exp.A vizsgált kezelés

    Induction (5 w): "Protocol IA" with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX Consolidation (6 w): "Consolidation extended+BZM" (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59) Extra-compartment phase (8 w): "Protocol M" with 6-MP, HD-MTX,IT MTX Reinduction (6 weeks): "Protocol II" with dexamethasone, vincristine, doxorubicin, PEG-L-asparaginase, IT MTX, cyclophosphamide, tioguanine, cytarabine Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR) Maintenance phase (until 2 yrs after initial diagnosis): 6-MP, MTX Erwinase is given in case of allergy to pegaspargase.

    Kezelés: Blinatumomab, Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Tioguanin, Vincristine és Erwinase

  • pB: early (non-)HR-standard/HR-standardMár használt kezelés, összehasonlításként

    Induction (5 w): as in other pB arms Consolidation (6 w/4 w): "Consolidation extended" (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT methotrexate, dexamethasone, vincristine, pegaspargase or "Consolidation short" (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide Reinduction (3x4 w): "Protocol III" given 3 times with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX Erwinase is given in case pegaspargase allergy. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX).

    Kezelés: Cyclophosphamide, Cytarabine, Daunorubicin, Myocet, Dexamethasone, Doxorubicin, Etoposide, Fludarabine Phosphate, Ifosfamide, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Tioguanin, Vincristine, Vindesine és Erwinase

  • pB: early HR-exp./HR-standardA vizsgált kezelés

    Induction (5 w): as in other pB arms Consolidation (6 w): "Consolidation extended+BZM" (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59) Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide Reinduction (3x4 w): as in arm "pB: early (non-)HR-standard/HR-standard" Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)

    Kezelés: Cyclophosphamide, Cytarabine, Daunorubicin, Myocet, Dexamethasone, Doxorubicin, Etoposide, Fludarabine Phosphate, Ifosfamide, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Tioguanin, Vincristine, Vindesine és Erwinase

  • pB: early (non-)HR-standard/HR-exp.A vizsgált kezelés

    Induction (5 w): as in other pB arms Consolidation (6 w/4 w): "Consolidation extended" (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or "Consolidation short" (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR) Reinduction (3x4 weeks): as in arm "pB: early (non-)HR-standard/HR-standard" Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX Erwinase is given in case of pegaspargase allergy. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)

    Kezelés: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Myocet, Dexamethasone, Doxorubicin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Tioguanin, Vincristine és Erwinase

  • pB: early HR-exp./HR-exp.A vizsgált kezelés

    Induction (5 w): as in other pB arms Consolidation (6 w): "Consolidation extended+BZM" (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59) Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR) Reinduction (3x4 weeks): as in arm "pB: early (non-)HR-standard/HR-standard" Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)

    Kezelés: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Myocet, Dexamethasone, Doxorubicin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Tioguanin, Vincristine és Erwinase

  • pB: early non-HR/SREgyéb csoport

    Induction (5 w): "Protocol IA" with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX Consolidation (4 w): "Consolidation short" with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX Extra-compartment phase (8 w): "Protocol M" with 6-MP, HD-MTX, IT MTX Reinduction (6 w): "Protocol II" with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX Erwinase is given in case of allergy to pegaspargase.

    Kezelés: Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Tioguanin, Vincristine és Erwinase

  • T: early non-SR-standard/(non-)HRMár használt kezelés, összehasonlításként

    Induction (5 w): "Protocol IA-Dexa" with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or "Protocol IA-CPM" with prednisolone instead of dexamethasone and additional CPM Consolidation (4 w): "Protocol IB regular" (control arm in randomization. R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX non-HR extra-compartment phase and reinduction: as in arm "pB: early non-HR/SR" HR intensified consolidation and reinduction: as in arm "pB: early (non-)HR-standard/HR-standard" Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)

    Kezelés: Cyclophosphamide, Cytarabine, Daunorubicin, Myocet, Dexamethasone, Doxorubicin, Etoposide, Fludarabine Phosphate, Ifosfamide, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Tioguanin, Vincristine, Vindesine és Erwinase

  • T: early non-SR-exp/(non-)HRA vizsgált kezelés

    Induction (5 w): "Protocol IA-Dexa" with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or "Protocol IA-CPM" with prednisolone instead of dexamethasone and additional CPM Consolidation (6 w): "Protocol IB long" (experimental arm in randomization R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX non-HR extra-compartment phase and reinduction: as in arm "pB: early non-HR/SR" HR intensified consolidation and reinduction: as in arm "pB: early (non-)HR-standard/HR-standard" Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)

    Kezelés: Cyclophosphamide, Cytarabine, Daunorubicin, Myocet, Dexamethasone, Doxorubicin, Etoposide, Fludarabine Phosphate, Ifosfamide, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Tioguanin, Vincristine, Vindesine és Erwinase

  • T: early SR/non-HREgyéb csoport

    Induction (5 w): "Protocol IA-Dexa" with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX Consolidation (4 w): "Protocol IB regular" with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX Extra-compartment phase (8 w): "Protocol M" with 6-MP, HD-MTX, IT MTX Reinduction (6 w): "Protocol II" with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX Erwinase is given in case of allergy to pegaspargase.

    Kezelés: Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Tioguanin, Vincristine és Erwinase

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
Illeszkedési kérdések
Forrás: NCT03643276: ki vehet részt
Publikációk
A regiszteradat frissítve
2025. április 6.